{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:37:18Z","timestamp":1787564238327,"version":"build-2736575974"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,5,20]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The long-term effectiveness of denosumab, an antireceptor activator of nuclear factor-\u03baB ligand monoclonal antibody, for increasing bone mineral density (BMD) and reducing fracture risk in postmenopausal women with osteoporosis (OP) has been demonstrated; however, the long-term effectiveness and safety in patients with rheumatic diseases (RDs) remain unclear. Therefore, the present study investigated the long-term effectiveness and safety of denosumab for OP in patients with RDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included patients who received denosumab between August 2013 and August 2022. We evaluated BMD at the lumbar spine for up to 7 years and at the femur for up to 3 years. The effects of glucocorticoid (GC) usage, age, and renal function on BMD in patients receiving denosumab were assessed. The retention rate and adverse events were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred sixty-five patients with RDs were enrolled (median age 66.5 years, 92.1% female, 68.5% receiving GC therapy). Lumbar spine BMD significantly increased over 7 years (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), whereas femoral neck, trochanter, and total hip BMD significantly increased for up to 3 years (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Lumbar spine BMD significantly increased regardless of GC dose, age, or renal dysfunction. The retention rate of denosumab at 7 years was 68.1%. The most common serious adverse event was infection. Two cases of osteonecrosis of the jaw and 10 new fractures were observed during treatment with denosumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study suggests that the long-term use of denosumab is an effective and generally safe option for increasing BMD in patients with RDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1321","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T08:25:18Z","timestamp":1748766318000},"page":"927-933","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8931-9200","authenticated-orcid":false,"given":"Karin","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-6948","authenticated-orcid":false,"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-8067","authenticated-orcid":false,"given":"Mai","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-8723","authenticated-orcid":false,"given":"Kotaro","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-074X","authenticated-orcid":false,"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"2025090105350887000_52.9.927.1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","article-title":"Glucocorticoid-induced osteoporosis update","volume":"31","author":"Adami","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2025090105350887000_52.9.927.2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3195"},{"key":"2025090105350887000_52.9.927.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken121"},{"key":"2025090105350887000_52.9.927.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.140"},{"key":"2025090105350887000_52.9.927.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.4.224"},{"key":"2025090105350887000_52.9.927.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.07.008"},{"key":"2025090105350887000_52.9.927.7","doi-asserted-by":"publisher","DOI":"10.1186\/ar3380"},{"key":"2025090105350887000_52.9.927.8","doi-asserted-by":"publisher","DOI":"10.1038\/46303"},{"key":"2025090105350887000_52.9.927.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3540"},{"key":"2025090105350887000_52.9.927.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2025090105350887000_52.9.927.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3705"},{"key":"2025090105350887000_52.9.927.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214827"},{"key":"2025090105350887000_52.9.927.13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2169\/internalmedicine.8560-21","article-title":"Efficacy of denosumab for osteoporosis in patients with rheumatic diseases","volume":"61","author":"Kaneko","year":"2022","journal-title":"Intern Med"},{"key":"2025090105350887000_52.9.927.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-013-0447-8"},{"key":"2025090105350887000_52.9.927.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-014-0586-6"},{"key":"2025090105350887000_52.9.927.16","doi-asserted-by":"publisher","DOI":"10.1007\/BF01622200"},{"key":"2025090105350887000_52.9.927.17","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3641"},{"key":"2025090105350887000_52.9.927.18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025090105350887000_52.9.927.19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025090105350887000_52.9.927.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208052"},{"key":"2025090105350887000_52.9.927.21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11657-021-00899-5","article-title":"Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study","volume":"16","author":"Ishida","year":"2021","journal-title":"Arch Osteoporos"},{"key":"2025090105350887000_52.9.927.22","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200108"},{"key":"2025090105350887000_52.9.927.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2022.10.009"},{"key":"2025090105350887000_52.9.927.24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/1756-185X.12424","article-title":"Rheumatological diseases and kidneys: a nephrologist\u2019s perspective","volume":"17","author":"Mittal","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"2025090105350887000_52.9.927.25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.547"},{"key":"2025090105350887000_52.9.927.26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.403"},{"key":"2025090105350887000_52.9.927.27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","article-title":"Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study","volume":"30","author":"Borek","year":"2019","journal-title":"Osteoporos Int"},{"key":"2025090105350887000_52.9.927.28","doi-asserted-by":"crossref","first-page":"116925","DOI":"10.1016\/j.bone.2023.116925","article-title":"Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: a retrospective study of patients with osteoporosis in a real-world clinical setting","volume":"177","author":"Cruchelow","year":"2023","journal-title":"Bone"},{"key":"2025090105350887000_52.9.927.29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000935"},{"key":"2025090105350887000_52.9.927.30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001235"},{"key":"2025090105350887000_52.9.927.31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"key":"2025090105350887000_52.9.927.32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00774-020-01089-y","article-title":"Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease","volume":"38","author":"Fujieda","year":"2020","journal-title":"J Bone Miner Metab"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:35:47Z","timestamp":1756730147000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.3899\/jrheum.2024-1321"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1321","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}